the IND grant for PW is great news. in contrast, the market has created a condition of negative expectation on the price per share, generating volatility and downward manipulation, trying to intercept packets of retail shares to be reset. operation I would say successful, but at the end of the games the resultant in the numbers generated, certifies that the purchases are superior to the sales intentions, therefore there is no doubt, that whoever forced the price downwards evidently repurchased even more shares at prices more convenient; those shares left in the field, by that part of retail that bets in the very short term, with a certain myopia compared to the real objectives of this company, in the next two quarters. Why PW's IND grant is great news? the phase 2 PW trial will be limited to 30 male and female subjects aged between 4 and 20 years. dosing will occur twice daily for 84 days. this means that if the trial starts by February, the company will have a certain reliable result by May; the remaining three trials 2591, are perfectly aligned in May, precisely on day 18. I therefore believe that Neuren as a strategic objective aims to conclude 4 trials simultaneously and given that nothing happens by chance, perhaps behind this ambitious result, there is something already scheduled for some time or an agreement with third parties for any.PW unlike Trofinetide is another world. the numbers and expectations of this trial are enormous compared to Trofinetide in the Rett variant. this indicates that the great and true value, the one that makes the big difference is on the 2591 project and on which it is worth betting.I consider it very probable and realistic, that in the second half of 2023, Neuren may no longer be independent.I recommend viewing the following recently published link, to understand what I'm talking about and what the market is trying to obfuscate.
https://www.digitaljournal.com/pr/human-growth-hormone-market-size-top-companies-industry-analysis-trends-latest-insights-and-forecast-to-2027
(20min delay)